PARP Inhibitor Pamiparib in HRD Mutated Protstate Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

PARP Inhibitor Pamiparib in HRD Mutated Protstate Cancer

Sponsor: BeiGene, Ltd.

Protocol BGB-290-202. A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD). PARP inhibitor pamiparib for patients with metastatic, castration resistant prostate cancer with a mutation inducing homologous recombination deficiency.